In May 2023, diversified digital health company Vitura Health (ASX: VIT) announced a joint venture with Canadian psychedelic company PharmAla Biotech, giving birth to its Melbourne-based psychedelics arm, Cortexa. Providing an update on the 50-50 venture, the Company has noted an “Australian first” win. Its MDMA bulk GMP (good manufacturing practice) Active Pharmaceutical Ingredient (API)
Read More
Bringing pharmaceutical weed to telehealth, medical cannabis company Vitura Health (ASX: VIT) has decided to acquire telehealth company Doctors on Demand for an aggregate consideration of $25 million. This deal includes an upfront cash payment, a deferred cash component, and an equity stake. The acquisition marks Vitura’s leap into new healthcare verticals, including urgent care,
Read More
Once again, medical cannabis producer Vitura Health (ASX: VIT) has become the only ASX-listed company operating in the medicinal cannabis space to both generate a profit and declare a dividend since its ASX initiation in 2019. The Company will pay a dividend to shareholders in respect of FY23. The Dividend, which will be paid at
Read More
Leading cannabis company providing a safe and reliable source of cannabis treatment products, Vitura Health (ASX: VIT) has released its financial results for the first half of FY2023, revealing a significant step up across the board following their recent business overhaul finalised earlier this year. You may not recognise the Company or its name just
Read More
Cannabis consumers rejoice, medicinal cannabis provider Cronos Australia (ASX:CAU) is very close to finally releasing its Canview platform to make the procurement of the drug an easy affair. The roll-out is happening across stages with the first one comprising a number of order fulfilment upgrades, process improvements and other efficiencies. It was deployed internally within
Read More